MAPT and Alzheimer disease: However, in a phase 1b trial investigating the antisense oligonucleotide termed BIIB080 in subjects with mild AD, a significant reduction of tau PET below baseline was observed in a small imaging cohort (n = 12) at week 100, likely through reducing the amount of tau protein that can be recruited in the modest ability of turnover in tangles [90, 91].